BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2025-08

189 industry Phase 2/3 trial readout(s) and 34 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2025-07 | 2025-09 →

FDA decision events

DateEventStatusCompanyDrugSource
2025-08-01FDA approvalapprovedBRACCOE-Z-DISKApproved 2025-08-01: E-Z-DISK (NDA219840 ORIG1)
2025-08-01FDA approvalapprovedHANDA THERAPPHYRAGOApproved 2025-08-01: PHYRAGO (NDA216099 SUPPL5)
2025-08-05Complete response lettercomplete responseAccord BioPharma, Inc.CRL 2025-08-05: Accord BioPharma, Inc. BLA 761147
2025-08-05FDA approvalapprovedTEVA PHARMS USAAJOVYApproved 2025-08-05: AJOVY (BLA761089 SUPPL31)
2025-08-06Complete response lettercomplete responseImmedica Pharma ABCRL 2025-08-06: Immedica Pharma AB BLA 761211
2025-08-06FDA approvalapprovedCHIMERIXMODEYSOApproved 2025-08-06: MODEYSO (NDA219876 ORIG1)
2025-08-08FDA approvalapprovedAVYXA HOLDINGSKYXATAApproved 2025-08-08: KYXATA (NDA219921 ORIG1)
2025-08-08FDA approvalapprovedGENENTECHACTEMRAApproved 2025-08-08: ACTEMRA (BLA125276 SUPPL149)
2025-08-08FDA approvalapprovedBOEHRINGER INGELHEIMHERNEXEOSApproved 2025-08-08: HERNEXEOS (NDA219042 ORIG1)
2025-08-12FDA approvalapprovedINSMED INC INSMBRINSUPRIApproved 2025-08-12: BRINSUPRI (NDA217673 ORIG1)
2025-08-13FDA AdComheldAdCom 2025-08-13: General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee
2025-08-14FDA approvalapprovedJANSSEN BIOTECHRYBREVANTApproved 2025-08-14: RYBREVANT (BLA761210 SUPPL9)
2025-08-14FDA approvalapprovedJANSSEN BIOTECHLAZCLUZEApproved 2025-08-14: LAZCLUZE (NDA219008 SUPPL2)
2025-08-15FDA approvalapprovedTONIX TNXPTONMYAApproved 2025-08-15: TONMYA (NDA219428 ORIG1)
2025-08-15FDA approvalapprovedNOVO NVOWEGOVY WEGOVY FLEXTOUCH WEGOVY HDApproved 2025-08-15: WEGOVY; WEGOVY FLEXTOUCH; WEGOVY HD (NDA215256 SUPPL24)
2025-08-15FDA approvalapprovedTHEA PHARMACYKLXApproved 2025-08-15: CYKLX (NDA218643 ORIG1)
2025-08-18Complete response lettercomplete responsePTC Therapeutics, Inc. PTCvatiquinone in the treatment of Friedreich’s Ataxia (FA)CRL 2025-08-18: PTC Therapeutics, Inc. NDA 220049 (vatiquinone in the treatment of Friedreich’s Ataxia (FA))
2025-08-18FDA approvalapprovedLundbeck Seattle BioPharmaceuticals, Inc.VYEPTIApproved 2025-08-18: VYEPTI (BLA761119 SUPPL10)
2025-08-21FDA approvalapprovedIONIS PHARMS INC IONSDAWNZERA (AUTOINJECTOR)Approved 2025-08-21: DAWNZERA (AUTOINJECTOR) (NDA219407 ORIG1)
2025-08-25FDA approvalapprovedACCORDCAMCEVI ETMApproved 2025-08-25: CAMCEVI ETM (NDA219745 ORIG1)
2025-08-25FDA approvalapprovedHIKMAKLOXXADOApproved 2025-08-25: KLOXXADO (NDA212045 SUPPL5)
2025-08-27Complete response lettercomplete responseVyluma, Inc.atropine sulphate ophthalmic solution, 0CRL 2025-08-27: Vyluma, Inc. NDA 217711 (atropine sulphate ophthalmic solution, 0)
2025-08-27Complete response lettercomplete responseOutlook Therapeutics, Inc. OTLKCRL 2025-08-27: Outlook Therapeutics, Inc. BLA 761320
2025-08-27Complete response lettercomplete responseSaol International Development Limitedsodium dichloroacetateCRL 2025-08-27: Saol International Development Limited NDA 218679 (sodium dichloroacetate)
2025-08-27FDA approvalapprovedDAY ONE BIOPHARMSOJEMDAApproved 2025-08-27: OJEMDA (NDA218033 SUPPL2)
2025-08-27FDA approvalapprovedTRAVERE TVTXFILSPARIApproved 2025-08-27: FILSPARI (NDA216403 SUPPL5)
2025-08-27FDA approvalapprovedDAY ONE BIOPHARMSOJEMDAApproved 2025-08-27: OJEMDA (NDA217700 SUPPL2)
2025-08-28FDA approvalapprovedXTM CONSULTINGLOPRESSORApproved 2025-08-28: LOPRESSOR (NDA218698 ORIG1)
2025-08-29FDA approvalapprovedEISAI INCLEQEMBI IQLIKApproved 2025-08-29: LEQEMBI IQLIK (BLA761375 ORIG1)
2025-08-29FDA approvalapprovedSHANGHAI HENLIUS BIOTECHBILDYOS; BILPREVDAApproved 2025-08-29: BILDYOS; BILPREVDA (BLA761444 ORIG1)
2025-08-29FDA approvalapprovedAMGEN INC AMGNOTEZLA; OTEZLA XRApproved 2025-08-29: OTEZLA; OTEZLA XR (NDA210745 ORIG2)
2025-08-29FDA approvalapprovedAMGEN INC AMGNOTEZLA; OTEZLA XRApproved 2025-08-29: OTEZLA; OTEZLA XR (NDA210745 ORIG1)
2025-08-29FDA approvalapprovedALMATICAESCITALOPRAMApproved 2025-08-29: ESCITALOPRAM (NDA219130 ORIG1)
2025-08-29FDA approvalapprovedGENZYME CORPWAYRILZApproved 2025-08-29: WAYRILZ (NDA219685 ORIG1)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2025-08 est.P2Medeor Therapeutics, Inc.NCT03606746 Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney TransplantsKidney Transplant Rejectionwithdrawn
2025-08 est.P1/P2Editas Medicine, Inc. EDITNCT04853576 A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)Sickle Cell Disease; Hemoglobinopathiesactive not recruiting45
2025-08 est.P2Philips Portuguesa S.A.NCT04903951 Impact of Early Ventilation in Stroke Outcomes in Patients With Sleep Apnea After First Ever StrokeStroke; Sleep Apneaunknown90
2025-08 est.P1/P2Smart Immune SASNCT04959903 Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCTHematological Malignanciesrecruiting36
2025-08 est.P1/P2Glaukos Corporation GKOSNCT05314738 Safety and Efficacy of Corneal Cross-linking in Subjects With KeratoconusProgressive Keratoconusunknown150
2025-08 est.P1/P2Cyclacel Pharmaceuticals, Inc.NCT05358379 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and LymphomaSolid Tumor, Adult Lymphomaunknown330
2025-08 est.P3Radius Pharmaceuticals, Inc. RDUFFNCT05387798 A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi SyndromePrader-Willi Syndromewithdrawn
2025-08 est.P3R-Pharm International, LLCNCT05432960 Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)Adult-Onset Still's Disease; AOSDwithdrawn
2025-08 est.P1/P2Guangzhou Jiayin Biotech LtdNCT05614531 Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1Spinal Muscular Atrophy Type Iunknown12
2025-08 est.P1/P2Selecta Biosciences, Inc.NCT05778877 A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMAMethylmalonic Acidemia (MMA)withdrawn
2025-08 est.P2/P3Kartos Therapeutics, Inc.NCT05797831 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial CancerEndometrial Cancerrecruiting268
2025-08 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05922345 Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer PNon-small Cell Lung Cancerunknown518
2025-08 est.P2Melius Pharma ABNCT05983471 Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)Idiopathic Pulmonary Fibrosis; Cough; IPF; Fibrotic Lung Disease; Chronic Cough; Coughingactive not recruiting40
2025-08 est.P2Jiangsu Pacific Meinuoke Bio Pharmaceutical Co LtdNCT06040346 Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium FalciparumMalariaunknown60
2025-08 est.P3Faes Farma, S.A.NCT06176560 Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.Colitis, Ulcerativeunknown376
2025-08 est.P3HanAll BioPharma Co., Ltd.NCT06400589 A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye DiseaseDry Eyesuspended750
2025-08 est.P2EyebioKorea, Inc.NCT06487039 Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular DegenerationNeovascular Age-related Macular Degeneration (nAMD)unknown50
2025-08 est.P2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06522828 A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer PatientsAdvanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancerunknown80
2025-08 est.P3Ache Laboratorios Farmaceuticos S.A.NCT06577077 Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic RhinitisRhinitis, Allergic, Perennialunknown432
2025-08 est.P3Shandong New Time Pharmaceutical Co., LTDNCT06819774 Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute UrticariaAcute Urticariarecruiting284
2025-08 est.P2Wellizen AustraliaNCT06963840 Effect of Theronomic Ova-All Care on Biomarkers of Ovarian Health in Adult Female With Polycystic Ovarian SyndromePolycystic Ovarian Syndrome (PCOS)active not recruiting16
2025-08 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT06981988 A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHLRelapsed/Refractory Indolent NHLnot yet recruiting80
2025-08 est.P2/P3AgelessRxNCT07092618 Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-CessationLongevity; GLP-1; Geroscience; Agingrecruiting150
2025-08-01P1/P2Grifols Therapeutics LLC GRFSNCT04722887 A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants WitAlpha1-Antitrypsin Deficiencycompleted17
2025-08-01P3Janssen Research & Development, LLCNCT05083169 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or DaratumumaMultiple Myelomaactive not recruiting587
2025-08-01P2Sparrow PharmaceuticalsNCT05307328 SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's SyndromeCushing's Syndrome I; Cushing Disease Due to Increased ACTH Secretion; Cortisol Excess; Cortisol; Hycompleted26
2025-08-01 est.P2/P3Shandong New Time Pharmaceutical Co., LTDNCT05408221 the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular CarcinomaHepatocellular Carcinomaunknown576
2025-08-01 est.P1/P2Shanghai Huaota Biopharmaceutical Co., Ltd.NCT05417321 A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid TumorsAdvanced Solid Tumor; NSCLCrecruiting80
2025-08-01 est.P1/P2BioSight Ltd.NCT05503355 A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AMLAML, Adultunknown80
2025-08-01P2Bristol-Myers Squibb BMYNCT05567458 A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.Beta-thalassemiaactive not recruiting94
2025-08-01P3Chemo ResearchNCT06019533 A Trial of Efficacy, Safety and Tolerability of LVDS (Levonorgestrel Vaginal Delivery System) During 13 CyclesContraceptioncompleted1039
2025-08-01 est.P2Beijing Tide Pharmaceutical Co., LtdNCT06102083 A Clinical Trial on the Treatment of Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosisunknown120
2025-08-01 est.P1/P2Frontera TherapeuticsNCT06492850 Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis PigmentosaX-Linked Retinitis Pigmentosa (XLRP)unknown32
2025-08-01 est.P2CSPC Ouyi Pharmaceutical Co., Ltd.NCT06511739 A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo PatientsNon-segmental Vitiligounknown144
2025-08-01P3Zhejiang Kanova Biopharmaceutical Co., LTDNCT07498634 Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active ASPhase IIIcompleted323
2025-08-02 est.P1/P2Betta Pharmaceuticals Co., Ltd.NCT05869240 BPB-101 in Subjects With Metastatic or Locally Advanced Solid TumorsSolid Tumorunknown388
2025-08-04P3Belite Bio, Inc BLTENCT05244304 Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt DiseaseStargardt Disease 1completed104
2025-08-04P3Bristol-Myers Squibb BMYNCT05625399 A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaMelanomaactive not recruiting579
2025-08-04P2TriGemX Bio, Inc.NCT06848075 A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of MigraineMigrainecompleted431
2025-08-05P2Merck Sharp & Dohme LLC MRKNCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)Uterine Cervical Neoplasms; Endometrial Neoplasms; Squamous Cell Carcinoma of Head and Neck; Gallblacompleted611
2025-08-05P2GlaxoSmithKlineNCT05276297 A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and ChroHepatitis B, Chroniccompleted174
2025-08-05P3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05526222 A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisAtopic Dermatitiscompleted443
2025-08-05P3Pathalys PharmaNCT05836220 Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2Secondary Hyperparathyroidism; End Stage Kidney Diseasecompleted412
2025-08-05 est.P3AkesoNCT05990127 A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerLocally Advanced or Metastatic NSCLCnot yet recruiting642
2025-08-05P1/P2Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT06703203 Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate VaccinePneumococcal Vaccinescompleted450
2025-08-05P3Gan & Lee Pharmaceuticals.NCT06780410 A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic AcidPrimary Hyperlipidemiacompleted245
2025-08-05P1/P2Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.NCT06824519 Clinical Trials of Quadrivalent Influenza VaccineInfluenza, Humanrecruiting620
2025-08-06P3Stallergenes GreerNCT05668390 Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o AsthmaAllergic Rhinoconjunctivitis; Birch Pollen Allergycompleted553
2025-08-06P2Sanofi SNYNCT05856331 Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD EmphysemaAlpha 1-Antitrypsin Deficiency; Emphysemacompleted99
2025-08-06P3Incyte Biosciences Japan GK INCYNCT06263478 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic GrChronic Graft-versus-host-diseaseactive not recruiting21
2025-08-07P1/P2Hoffmann-La RocheNCT03677154 Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as MoDiffuse Large B-cell Lymphomacompleted188
2025-08-07P1/P2Heron Neutron Medical Corp.NCT06668987 A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent MeningiomaMeningioma; Boron Neutron Capture Therapycompleted10
2025-08-07P2Nanjing Minova Pharmaceutical Co., Ltd.NCT06963580 Efficacy of MI078 Capsules in Treating Postpartum DepressionPostpartum Depressioncompleted72
2025-08-08P3AbbVie ABBVNCT03850782 Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionOpen-Angle Glaucoma; Ocular Hypertensioncompleted515
2025-08-08P3Hoffmann-La RocheNCT04961996 A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With EstrEarly Breast Canceractive not recruiting4170
2025-08-08P3Eli Lilly and Company LLYNCT05872620 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesObesity; Overweight; Type 2 Diabetescompleted1613
2025-08-08P1/P2Sanofi SNYNCT06508489 A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological MalignanciesAcute Myeloid Leukemiaterminated7
2025-08-08P2Latigo Biotherapeutics LTGONCT06774625 This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third MolarsAcute Pain, Postoperativecompleted250
2025-08-10 est.P2Xi'An Aolitai Pharmaceutical Technology Co LtdNCT06019936 A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in DILI SubjectsDrug-Induced Liver Injury; Cholestatic Liver Injury; Mixed Liver Injuryunknown80
2025-08-11P1/P2Genmab GMABNCT05491317 A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid TumorsNon-CNS Tumorterminated13
2025-08-11P3CelgeneNCT06045806 A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in AdulMultiple Myelomaactive not recruiting79
2025-08-11P2Chiesi Farmaceutici S.p.A.NCT06900816 A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001Asthmacompleted50
2025-08-11P3Colgate Palmolive CLNCT06956599 Hypersensitivity Reduction Efficacy: 5% Potassium Nitrate Toothpaste Compared to Colgate Cavity Protection ToothpasteDentin Hypersensitivitycompleted80
2025-08-12P2Merck Sharp & Dohme LLC MRKNCT03742895 Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination DAdvanced Solid Neoplasmsactive not recruiting329
2025-08-12P1/P2Clarion Cells, Inc.NCT04631406 A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)Ischemic Strokeactive not recruiting27
2025-08-12P2Dr. Falk Pharma GmbHNCT05621811 Different Doses of Naronapride vs. Placebo in GastroparesisGastroparesiscompleted328
2025-08-12P3AstraZeneca AZNNCT06075095 A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation PrCOPD (Chronic Obstructive Pulmonary Disease)completed297
2025-08-12P2Evergreen Therapeutics, Inc.NCT07281105 EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety StudyNeuropsychiatric Systemic Lupus Erythematosus; Systemic Lupus Erythematosus (SLE); Cognitive Impairmcompleted131
2025-08-13P2AL-S PharmaNCT05039099 A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALSAmyotrophic Lateral Sclerosiscompleted73
2025-08-13P3Boehringer IngelheimNCT05285982 A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)Lung Diseases, Interstitialcompleted54
2025-08-13P2Novartis Pharmaceuticals NVSNCT05384587 Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia - Chronic Phaseactive not recruiting34
2025-08-13P2Noema Pharma AGNCT06385795 A Study of NOE-115 in Women With Vasomotor Symptoms Due to MenopauseMenopause Syndrome; Menopause; Hot Flashescompleted40
2025-08-13P3Innostellar Biotherapeutics Co.,LtdNCT07054632 Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 MutationsInherited Retinal Dystrophy Associated With RPE65 Mutationsactive not recruiting30
2025-08-14P3CelgeneNCT04991935 Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisEosinophilic Esophagitiscompleted367
2025-08-14P2Tvardi Therapeutics, Incorporated TVRDNCT05671835 Study of TTI-101 in Participants With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosiscompleted100
2025-08-14P2Flamingo Therapeutics NVNCT05814666 Activity and Safety of Danvatirsen and Pembrolizumab in HNSCCHNSCCterminated69
2025-08-14P3Hanmi Pharmaceutical Company Limited HAFCNCT06174779 A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes MellitusObesitycompleted448
2025-08-14P3MoonLake Immunotherapeutics AG MLTXNCT06411379 Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppuratiHidradenitis Suppurativacompleted418
2025-08-14 est.P2PDFE Pharma Innovations FZCONCT07011485 A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.Alopecia, Androgenetic; Baldness; Androgenetic Alopecia (AGA)active not recruiting15
2025-08-14P2Eli Lilly and Company LLYNCT07085468 A Study of LY3549492 in Healthy Weight Adult ParticipantsHealthyterminated1
2025-08-15P3AiCuris Anti-infective Cures AGNCT03073967 Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in ImmunocompromisedHSV Infectioncompleted158
2025-08-15P3Teva Branded Pharmaceutical Products R&D LLCNCT04530110 A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and AdolescentsMigrainecompleted499
2025-08-15P1/P2Erasca, Inc. ERASNCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal MalignanciesMetastatic Colorectal Cancer; Metastatic Pancreatic Ductal Adenocarcinomacompleted101
2025-08-15P1/P2Dragonfly Therapeutics DFLINCT05597839 Study of DF9001 in Patients With Advanced Solid TumorsSolid Tumor, Adultcompleted24
2025-08-15P3BioXcel Therapeutics Inc BTAIQNCT05658510 Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)Agitation,Psychomotor; Bipolar I Disorder; Bipolar II Disorder; Schizophrenia; Schizoaffective Disorcompleted452
2025-08-15P3Organogenesis ORGONCT06000410 A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the KneeKnee Osteoarthritiscompleted594
2025-08-15P1/P2Implicit BioscienceNCT06275893 IC14 (Atibuclimab) in Arrhythmogenic CardiomyopathyArrhythmogenic Right Ventricular Dysplasia; Arrhythmogenic Left Ventricular Cardiomyopathy; Arrhythmcompleted1
2025-08-15P2Beijing Wehand-Bio Pharmaceutical Co., LtdNCT06513364 Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast CancerBreast Cancercompleted40
2025-08-15P1/P2Seqker Biosciences, Inc.NCT06614140 Personalized Neoantigen Cancer Vaccine for Patients With Solid TumorsCancer; Solid Tumor, Adultcompleted8
2025-08-15P2Shandong Suncadia Medicine Co., Ltd.NCT06671821 Long-term Efficacy and Safety of HRS-7535 Tablets in Obese SubjectsChronic Weight Managementcompleted81
2025-08-16P3Jiangsu HengRui Medicine Co., Ltd.NCT04619433 A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.Non-squamous Non-small-cell Lung Cancerterminated48
2025-08-17P3AstraZeneca AZNNCT06168409 A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant HypertensionResistant Hypertensioncompleted218
2025-08-18 est.P3Biogen BIIBNCT03637387 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaTrigeminal Neuralgiawithdrawn
2025-08-18P2/P3Recursion Pharmaceuticals Inc. RXRXNCT05130866 Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasNeurofibromatosis Type 2terminated25
2025-08-18P2ReveraGen BioPharma, Inc.NCT05166109 A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)Becker Muscular Dystrophycompleted46
2025-08-18P3Laboratorios Sophia S.A de C.V.NCT05217680 Clinical Study to Evaluate PRO-169 for Diabetic Macular EdemaDiabetic Macular Edemacompleted509
2025-08-18P2AkesoNCT05247684 AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLCResectable Non-small Cell Lung Canceractive not recruiting90
2025-08-18P1/P2iOncturaNCT05586516 A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic CancerMetastatic Pancreatic Cancercompleted16
2025-08-18P2Replimune, Inc. REPLNCT05733611 RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCRefractory Metastatic Colorectal Cancer; pMMR; MSSterminated5
2025-08-18P3Jiangsu HengRui Medicine Co., Ltd.NCT06139393 Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in AdultsGout With Hyperuricemia in Adultscompleted765
2025-08-18P1/P2Genmab GMABNCT06171789 PRO1107 in Patients With Advanced Solid TumorsEndometrial Cancer; Ovarian Cancer; Triple Negative Breast Cancer; GastroEsophageal Cancer; Non-smalterminated33
2025-08-19P1/P2Lumicell, Inc.NCT03834272 Feasibility of the LUM Imaging System for Peritoneal Surface MalignanciesPeritoneal Metastasescompleted18
2025-08-19P3Merck Sharp & Dohme LLC MRKNCT04246177 Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With ICarcinoma, Hepatocellularterminated480
2025-08-19 est.P3Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT05913037 FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform NeurofibromasNeurofibromatosis 1; Plexiform Neurofibroma; NF1active not recruiting167
2025-08-19P3ACADIA Pharmaceuticals Inc. ACADNCT06173531 Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeHyperphagia in Prader-Willi Syndromecompleted175
2025-08-19P3Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.NCT06417281 Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid(5-ALA)5-aminolevulinic Acid; Malignant Glioma of Braincompleted86
2025-08-19P2Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT06854952 A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or ObesityOverweight or Obesitycompleted167
2025-08-19 est.P2Shaanxi Micot Pharmaceutical Technology Co., Ltd.NCT06976177 Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance DialysisSecondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysisrecruiting310
2025-08-20P1/P2CelgeneNCT03374085 A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)Multiple Myelomaterminated200
2025-08-20P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05815862 Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian CancerAdvanced Lung Cancer; Ovarian Cancercompleted29
2025-08-20P1/P2Takeda TAKNCT05886491 A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid LeukemiaLeukemiaterminated16
2025-08-20P3BayerNCT05901831 A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (ChChronic Kidney Disease; Type 1 Diabetes Mellituscompleted242
2025-08-20P3Laboratorios Silanes S.A. de C.V.NCT07328022 Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and SynovitisBursitis; Tendinitis; Synovitiscompleted89
2025-08-21P3Sanofi SNYNCT06224348 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on BacDermatitis Atopiccompleted643
2025-08-21P3ModernaTX, Inc.NCT06602024 A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgeSeasonal Influenzacompleted40805
2025-08-22P2Iovance Biotherapeutics, Inc. IOVANCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaCervical Carcinomaterminated210
2025-08-22P3Ionis Pharmaceuticals, Inc. IONSNCT04849741 A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)Alexander Diseaseactive not recruiting54
2025-08-22P3AstraZeneca AZNNCT04877691 Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusSystemic Lupus Erythematosusactive not recruiting367
2025-08-22P3Hutchison Medipharma LimitedNCT05015608 Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationNon-small Cell Lung Cancercompleted216
2025-08-22P2Biofrontera Inc. BFRINCT05080764 Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic TherapAcne Vulgariscompleted120
2025-08-22P1/P2NiKang Therapeutics, Inc.NCT05119335 A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell CarcinomaccRCC; Clear Cell Renal Cell Carcinoma; Kidney Cancer; Kidney Neoplasms; Renal Cancer; Renal Neoplasterminated120
2025-08-22P3Calcilytix Therapeutics, Inc., a BridgeBio companyNCT05680818 Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1Autosomal Dominant Hypocalcemia (ADH)active not recruiting67
2025-08-22P2Beijing Joekai Biotechnology LLCNCT05811442 Study of 50561 in Patients With Mild or Moderate Alzheimer's DiseaseAlzheimer's Diseasecompleted68
2025-08-22P2Crinetics Pharmaceuticals Inc.NCT05907291 Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasiacompleted38
2025-08-22P3Eli Lilly and Company LLYNCT06045221 A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminType 2 Diabetescompleted1698
2025-08-22P3Lynk Pharmaceuticals Co., LtdNCT06276998 A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)Rheumatoid Arthritiscompleted430
2025-08-22P3Wuhan YZY Biopharma Co., Ltd.NCT06432296 Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific AntibodyMalignant Ascitesactive not recruiting312
2025-08-23 est.P1/P2LetolabNCT06384235 Phase II Clinical Study of LTC004 in Patients With mCRCLocally Advanced or Metastatic CRCunknown30
2025-08-25P1/P2Merck Sharp & Dohme LLC MRKNCT04305041 Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory MelMelanomacompleted100
2025-08-25P1/P2Incyte Corporation INCYNCT04370704 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced MalignancMelanomacompleted61
2025-08-25P3AstraZeneca AZNNCT05374512 A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who AreBreast Canceractive not recruiting644
2025-08-25 est.P2Beijing InnoCare Pharma Tech Co., Ltd.NCT05688696 Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus ErythematosusSystemic Lupus Erythematosus, SLEunknown186
2025-08-25P3Pfizer PFENCT05810038 A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.Migrainecompleted787
2025-08-25P2Vaxcyte, Inc. PCVXNCT05844423 Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy InfantsPneumococcal Vaccinescompleted802
2025-08-25P1/P2BioNTech SE BNTXNCT05988203 A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox VaccinesMonkeypoxcompleted96
2025-08-25P3Chongqing Claruvis Pharmaceutical Co., Ltd.NCT06583486 A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe GlabellarModerate to Severe Glabellar Linescompleted488
2025-08-25P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06644417 Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBVHBV Infection With LLVcompleted122
2025-08-25P3Beijing Suncadia Pharmaceuticals Co., LtdNCT06723652 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Homozygous Familial Hypercholesterolemiacompleted55
2025-08-25P3Qilu Pharmaceutical Co., Ltd.NCT07081256 To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.Chemotherapy-Induced Nausea and Vomitingcompleted665
2025-08-26P1/P2JW PharmaceuticalNCT03055286 Clinical Study of CWP232291 in Acute Myeloid Leukemia PatientsAcute Myeloid Leukemiaterminated15
2025-08-26P3Eurofarma Laboratorios S.A.NCT05118672 Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold TreatmentCold; Flu Symptomcompleted567
2025-08-26P3Otsuka Pharmaceutical Co., Ltd.NCT05326347 A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With SchizophreniaSchizophreniacompleted247
2025-08-26P1/P2SelecxineNCT05525247 A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in CombinationAdvanced Solid Tumorterminated27
2025-08-26P2/P3Sutro Biopharma, Inc. STRONCT05870748 REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian CancerOvarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Platinuterminated600
2025-08-26P3Regeneron Pharmaceuticals REGNNCT06491914 A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Neovascular Age-Related Macular Degeneration; Diabetic Macular Edemaactive not recruiting1126
2025-08-26P1/P2Inventprise Inc.NCT06611371 Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.Group B Streptococcal Infectionsactive not recruiting600
2025-08-26P3InnoNext SarlNCT07031973 The Effect of Micronutrient Supplementation on Nutrition Status and Well-beingMicronutrient Deficienciescompleted150
2025-08-26P2Beijing Dayspring Pharmaceutical Technology Co., LtdNCT07076706 Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic AlopeciaMale Pattern of Hair Loss, Androgenic Alopecia; Androgenetic Alopecia (AGA)completed110
2025-08-26P3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07704684 Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With AmlodipineEssential Hypertensioncompleted376
2025-08-27 est.P3Saol Therapeutics IncNCT02616484 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:Pyruvate Dehydrogenase Complex Deficiencyactive not recruiting34
2025-08-27P3Janssen Research & Development, LLCNCT04899336 A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic EschInvasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Preventioncompleted17797
2025-08-27P3Pulnovo Medical (Wuxi) Co., Ltd.NCT05824923 A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart FailurePulmonary Hypertension; Heart Failure With Reduced Ejection Fraction; Hypertension; Vascular Diseaseactive not recruiting264
2025-08-27P3Nielsen BioSciences, Inc.NCT05889845 Candin for the Treatment of Common WartsCommon Warts (Verruca Vulgaris)completed330
2025-08-27P1/P2Hoffmann-La RocheNCT05908786 A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular CarcinomaCarcinoma, Hepatocellularterminated62
2025-08-27P1/P2Sanofi Pasteur, a Sanofi Company SNYNCT06128733 Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and AdolescentsMeningococcal Immunisation; Healthy Volunteerscompleted1215
2025-08-27P2LimmaTech Biologics AGNCT06523231 Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.Shigellosiscompleted110
2025-08-27P3CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT06604624 Semaglutide in Treatment of ObesityWeight Managementcompleted462
2025-08-28P2Mercator MedSystems, Inc.NCT04858776 Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVTIliofemoral; Thrombosisactive not recruiting60
2025-08-28P3Averitas Pharma, Inc.NCT04967664 Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After SurgeryPost Surgical Neuropathic Paincompleted412
2025-08-28P1/P2Abcuro, Inc.NCT05532722 ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)T-cell Large Granular Lymphocytic Leukemiacompleted21
2025-08-28P1/P2Cellcolabs Clinical SPV LimitedNCT06063590 A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty PatientsAging Frailtycompleted12
2025-08-28P2PepGen Inc PEPGNCT06079736 A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping TreatmentDuchenne Muscular Dystrophyterminated7
2025-08-28P2Zenas BioPharma (USA), LLC ZBIONCT06564311 A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)Relapsing Multiple Sclerosisactive not recruiting93
2025-08-29P3Harmony Biosciences Management, Inc. HRMYNCT04977986 Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X SyndromeFragile X Syndrome; Fragile X Syndrome (FXS)completed257
2025-08-29P1/P2Kura Oncology, Inc. KURANCT04997902 Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)HNSCCcompleted45
2025-08-29P1/P2Jazz Pharmaceuticals JAZZNCT05027139 A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing CancerHER2-expressing Cancerscompleted52
2025-08-29P2Vedanta Biosciences, Inc.NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative ColitisUlcerative Colitis; Colitis, Ulcerativeterminated114
2025-08-29P3RHEACELL GmbH & Co. KGNCT05464381 Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)Epidermolysis Bullosaactive not recruiting91
2025-08-29 est.P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05720026 Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast CancerHER2-positive Breast Cancerunknown560
2025-08-29P3RHEACELL GmbH & Co. KGNCT05838092 Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)Epidermolysis Bullosaactive not recruiting9
2025-08-29 est.P2Keros Therapeutics, Inc. KROSNCT05927012 A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency AnemiIron Deficiency Anemiawithdrawn
2025-08-30 est.P1/P2Binhui Biopharmaceutical Co., Ltd.NCT03866525 OH2 Oncolytic Viral Therapy in Solid TumorsSolid Tumor; Gastrointestinal Cancerrecruiting300
2025-08-30P2Jazz Pharmaceuticals JAZZNCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal AdenocarHER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Ccompleted74
2025-08-30 est.P1/P2Advanced Imaging Projects, LLCNCT04469127 A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.Breast Cancer Stage IVunknown100
2025-08-30P1/P2TCR2 TherapeuticsNCT05451849 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerMesothelioma; Mesotheliomas Pleural; Mesothelioma, Malignant; Mesothelioma Peritoneum; Ovarian Canceterminated14
2025-08-30 est.P3Beijing Shenogen Biomedical Co., LtdNCT05594927 Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker EnrichmentHepatocellular Carcinomaunknown261
2025-08-30 est.P2BRIM Biotechnology Inc.NCT05927428 Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic KeratitisNeurotrophic Keratitisunknown12
2025-08-30 est.P1/P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06008366 A Phase 1/2 Study of 7MW3711 in Advanced Solid TumorsAdvanced Solid Tumorunknown281
2025-08-30 est.P1/P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06008379 A Study of 7MW3711 in Subjects With Advanced Solid TumorsAdvanced Solid Tumorunknown164
2025-08-30 est.P1/P2Biocity Biopharmaceutics Co., Ltd.NCT06055348 SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian CancerSerous Ovarian Cancer; Advanced Ovarian Cancerunknown112
2025-08-30 est.P3Chengdu Brilliant Pharmaceutical Co., Ltd.NCT06339086 Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 DiabetesType 2 Diabetes Mellitusunknown478
2025-08-30P1/P2Evopoint Biosciences Inc.NCT06558513 To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced TumorsAdvanced Tumor; Lymphomacompleted120
2025-08-30P2Shaanxi Micot Pharmaceutical Technology Co., Ltd.NCT06690242 MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney DiseaseSecondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysiscompleted115
2025-08-30P2CAGE Bio Inc.NCT06810050 Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic DermatitisAtopic Dermatitis (AD)completed180
2025-08-30P2CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT07421232 A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed HyperlipidemiaHypercholesterolemia and Mixed Hyperlipidemiacompleted156
2025-08-31P3AutotelicbioNCT05573477 Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II DiabetesEssential Hypertension; Diabetes Mellitus, Type 2completed255
2025-08-31 est.P1/P2Renata PLCNCT06531018 Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.Primary Immune Thrombocytopeniarecruiting100
2025-08-31 est.P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06654440 A Trial of SHR-A2102 for Treatment of Advanced Gynecological MalignancyAdvanced Gynecological Malignancyunknown100
2025-08-31 est.P1/P2Beijing Anlong Biopharmaceutical Co., Ltd.NCT06707753 Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMDWet Age-related Macular Degeneration (wAMD)active not recruiting21

← 2025-07 | 2025-09 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.